Clémence Bussiere1,2, Pauline Chauvin3,4, Jean-Michel Josselin5, Christine Sevilla-Dedieu6. 1. ERUDITE (CNRS-EA437), University of Paris Est Créteil, Paris, France. 2. MGEN Foundation for Public Health, Paris, France. 3. LIRAES (URP4470), Université Paris Cité, F-75006, Paris, France. pauline.chauvin@parisdescartes.fr. 4. Centre des Saints-Pères, 45 rue des Saints-Pères, 75006, Paris, France. pauline.chauvin@parisdescartes.fr. 5. CREM (CNRS-UMR6211), University of Rennes 1, Rennes, France. 6. LIRAES (URP4470), Université Paris Cité, F-75006, Paris, France.
Abstract
BACKGROUND: Managing type 2 diabetes represents a major public health concern due to its important and increasing prevalence. Our study investigates the impact of taking incretin-based medication on the risk of being hospitalized and the length of hospital stay for individuals with type 2 diabetes. METHOD: We use claim panel data from 2011 to 2015 and provide difference-in-differences (DID) estimations combined with matching techniques to better ensure the treatment and control groups' comparability. Our propensity score selects individuals according to their probability of taking an incretin-based treatment in 2013 (N = 2,116). The treatment group includes individuals benefiting from incretin-based treatments from 2013 to 2015 and is compared to individuals not benefiting from such a treatment but having a similar probability of taking it. RESULTS: After controlling for health-related and socio-economic variables, we show that benefiting from an incretin-based treatment does not significantly impact the probability of being hospitalized but does significantly decrease the annual number of days spent in the hospital by a factor rate of 0.621 compared with the length of hospital stays for patients not benefiting from such a treatment. CONCLUSION: These findings highlight the potential implications for our health care system in case of widespread use of these drugs among patients with severe diabetes.
BACKGROUND: Managing type 2 diabetes represents a major public health concern due to its important and increasing prevalence. Our study investigates the impact of taking incretin-based medication on the risk of being hospitalized and the length of hospital stay for individuals with type 2 diabetes. METHOD: We use claim panel data from 2011 to 2015 and provide difference-in-differences (DID) estimations combined with matching techniques to better ensure the treatment and control groups' comparability. Our propensity score selects individuals according to their probability of taking an incretin-based treatment in 2013 (N = 2,116). The treatment group includes individuals benefiting from incretin-based treatments from 2013 to 2015 and is compared to individuals not benefiting from such a treatment but having a similar probability of taking it. RESULTS: After controlling for health-related and socio-economic variables, we show that benefiting from an incretin-based treatment does not significantly impact the probability of being hospitalized but does significantly decrease the annual number of days spent in the hospital by a factor rate of 0.621 compared with the length of hospital stays for patients not benefiting from such a treatment. CONCLUSION: These findings highlight the potential implications for our health care system in case of widespread use of these drugs among patients with severe diabetes.
Authors: Young Gun Kim; Dong Gyu Park; So Young Moon; Ja Young Jeon; Hae Jin Kim; Dae Jung Kim; Kwan Woo Lee; Seung Jin Han Journal: Diabetes Metab J Date: 2019-10-23 Impact factor: 5.376
Authors: Daniel J Drucker; Steven I Sherman; Fred S Gorelick; Richard M Bergenstal; Robert S Sherwin; John B Buse Journal: Diabetes Care Date: 2010-02 Impact factor: 19.112